Literature DB >> 23417858

Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis.

P Chusorn1, N Namwat, W Loilome, A Techasen, C Pairojkul, N Khuntikeo, A Dechakhamphu, C Talabnin, W Chan-On, C K Ong, B T Teh, P Yongvanit.   

Abstract

MicroRNA, an endogenous noncoding RNA modulating gene expression, is a key molecule that by its dysregulation plays roles in inflammatory-driven carcinogenesis. This study aimed to investigate the role of oncomiR miR-21 and its target, the programmed cell death 4 (PDCD4) in tumor growth and metastasis of the liver fluke Opisthorchis viverrini-associated cholangiocarcinoma (CCA). The expression levels of miR-21 and PDCD4 were analyzed using the TaqMan miRNA expression assay and immunohistochemistry in liver tissues of both O. viverrini plus N-nitrosodimethylamine (NDMA)-treated hamsters and human CCA samples (n=23 cases). The functional assay for miR-21 was performed in CCA cell lines by the anti-miR-21 and pre-miR-21 transfection procedures. The peak of miR-21 levels were reached at 2 (hyperplastic lesions) and 6 (CCA) months of the O. viverrini plus NDMA-induced group and had a reverse response with its target PDCD4 proteins. In human CCA, miR-21 was overexpressed in tumor tissues when compared with nontumor tissues (P=0.0034) and had a negative correlation with PDCD4 protein (P=0.026). It was also found that high expression of miR-21 was significantly correlated with shorter survival (P<0.05) and lymph node metastasis (P=0.037) of CCA patients. Transient transfection of pre-miR-21 reduced the PDCD4 level and resulted in an increase of M213 CCA cell growth and wound-induced migration ability. These results indicated that miR-21 plays a role in the carcinogenesis and metastasis of O. viverrini-associated CCA by suppressing the function of PDCD4. Modulation of aberrantly expressed miR-21 may be a useful strategy to inhibit tumor cell phenotypes or improve response to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23417858     DOI: 10.1007/s13277-013-0688-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  60 in total

1.  Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases.

Authors:  N Namwat; J Puetkasichonpasutha; W Loilome; P Yongvanit; A Techasen; A Puapairoj; B Sripa; W Tassaneeyakul; N Khuntikeo; S Wongkham
Journal:  J Gastroenterol       Date:  2010-11-13       Impact factor: 7.527

2.  MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma.

Authors:  Changzheng Liu; Jia Yu; Shuangni Yu; Robert M Lavker; Lei Cai; Wei Liu; Kegong Yang; Xiaodong He; Songsen Chen
Journal:  J Hepatol       Date:  2010-04-04       Impact factor: 25.083

3.  Ultrastructural and immunohistochemical analysis of cholangiocarcinoma in immunized Syrian golden hamsters infected with Opisthorchis viverrini and administered with dimethylnitrosamine.

Authors:  S Tesana; Y Takahashi; P Sithithaworn; K Ando; T Sakakura; W Yutanawiboonchai; C Pairojkul; W Ruangjirachuporn
Journal:  Parasitol Int       Date:  2000-09       Impact factor: 2.230

4.  Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells.

Authors:  Lisa B Frankel; Nanna R Christoffersen; Anders Jacobsen; Morten Lindow; Anders Krogh; Anders H Lund
Journal:  J Biol Chem       Date:  2007-11-08       Impact factor: 5.157

5.  The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma.

Authors:  Lei Chen; He-Xin Yan; Wen Yang; Liang Hu; Le-Xin Yu; Qiong Liu; Liang Li; Dan-Dan Huang; Jin Ding; Feng Shen; Wei-Ping Zhou; Meng-Chao Wu; Hong-Yang Wang
Journal:  J Hepatol       Date:  2008-11-21       Impact factor: 25.083

6.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.

Authors:  Shuomin Zhu; Hailong Wu; Fangting Wu; Daotai Nie; Shijie Sheng; Yin-Yuan Mo
Journal:  Cell Res       Date:  2008-03       Impact factor: 25.617

Review 7.  Cholangiocarcinoma: lessons from Thailand.

Authors:  Banchob Sripa; Chawalit Pairojkul
Journal:  Curr Opin Gastroenterol       Date:  2008-05       Impact factor: 3.287

8.  MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).

Authors:  Shuomin Zhu; Min-Liang Si; Hailong Wu; Yin-Yuan Mo
Journal:  J Biol Chem       Date:  2007-03-15       Impact factor: 5.157

9.  MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G.

Authors:  Yang Chen; Wei Liu; Tengfei Chao; Yu Zhang; Xingqi Yan; Yanhua Gong; Boqin Qiang; Jiangang Yuan; Maosheng Sun; Xiaozhong Peng
Journal:  Cancer Lett       Date:  2008-11-13       Impact factor: 8.679

10.  Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini.

Authors:  Banchob Sripa; Bandit Thinkhamrop; Eimorn Mairiang; Thewarach Laha; Sasithorn Kaewkes; Paiboon Sithithaworn; Maria Victoria Periago; Vajarabhongsa Bhudhisawasdi; Ponlapat Yonglitthipagon; Jason Mulvenna; Paul J Brindley; Alex Loukas; Jeffrey M Bethony
Journal:  PLoS Negl Trop Dis       Date:  2012-05-22
View more
  30 in total

Review 1.  New insights into MicroRNAs involves in drug resistance in diffuse large B cell lymphoma.

Authors:  Xin Yu; Zheng Li
Journal:  Am J Transl Res       Date:  2015-12-15       Impact factor: 4.060

2.  Spaceflight alters expression of microRNA during T-cell activation.

Authors:  Millie Hughes-Fulford; Tammy T Chang; Emily M Martinez; Chai-Fei Li
Journal:  FASEB J       Date:  2015-08-14       Impact factor: 5.191

Review 3.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 4.  MicroRNAs and benign biliary tract diseases.

Authors:  Sergio A Gradilone; Steven P O'Hara; Tetyana V Masyuk; Maria Jose Lorenzo Pisarello; Nicholas F LaRusso
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

Review 5.  The role of miRNAs in cholangiocarcinoma.

Authors:  Jessica A Howell; Shahid A Khan
Journal:  Hepat Oncol       Date:  2016-03-29

Review 6.  Regulation of microRNAs in cancer metastasis.

Authors:  Juliette M C Bouyssou; Salomon Manier; Daisy Huynh; Samar Issa; Aldo M Roccaro; Irene M Ghobrial
Journal:  Biochim Biophys Acta       Date:  2014-02-22

Review 7.  Molecular diagnosis of intrahepatic cholangiocarcinoma.

Authors:  Hiroaki Haga; Tushar Patel
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-09-29       Impact factor: 7.027

Review 8.  Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma.

Authors:  Hiroaki Haga; Irene Yan; Kenji Takahashi; Joseph Wood; Tushar Patel
Journal:  Gene Expr       Date:  2014

9.  A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma.

Authors:  Amy L Collins; Sylwia Wojcik; James Liu; Wendy L Frankel; Hansjuerg Alder; Lianbo Yu; Thomas D Schmittgen; Carlo M Croce; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

10.  MicroRNAs in Cholangiopathies.

Authors:  Steven P O'Hara; Sergio A Gradilone; Tetyana V Masyuk; James H Tabibian; Nicholas F LaRusso
Journal:  Curr Pathobiol Rep       Date:  2014-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.